Document:

Amendment #1 to Patent Agreement

 Exhibit 10.7 
 AMENDMENT NO. 1 
 TO 
 PATENT RIGHTS AND RELATED ASSETS PURCHASE AGREEMENT 
 THIS AMENDMENT NO. 1 TO
THE PATENT RIGHTS AND RELATED ASSETS PURCHASE AGREEMENT (this “Amendment”), dated as of February 23rd, 2007, is by and between VIA PHARMACEUTICALS, INC., a Delaware corporation having an address of 750 Battery St., Suite 330, San
Francisco, California 94111 (the “Acquirer”), and NEURO3D, S.A., a French corporation having an address of 130 rue de la Mer Rouge, F-68200, Mulhouse, France (the “Company”). 
 Recitals 
 WHEREAS, the Acquirer and
the Company are parties to that certain Patent Rights and Related Assets Purchase Agreement, dated as of January 25th, 2007 (the “Purchase Agreement”); and 
 WHEREAS, the Acquirer and the Company desire to amend said Purchase Agreement as more fully described herein. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows: 
 1. Capitalized Terms. Capitalized Terms used, but not defined, herein, shall have the meanings ascribed to such terms in the Purchase Agreement.

 2. Amendments to Purchase Agreement. 
 (a) Purchase Price. Section 2.2 of the Purchase Agreement is hereby deleted in its entirety, and the following new Section 2.2 shall be substituted in lieu thereof: 
 “2.2 Purchase Price. The aggregate purchase price payable by the Acquirer for the Acquired Assets (the “Purchase
Price”) shall be $1,800,000 in U.S. currency. US $1,600,000 of the Purchase Price paid by the Acquirer is in consideration for the Co-owned Patents. The Purchase Price shall be paid by the Acquirer to the Company in two installments as
set forth in Sections 2.2(a) and 2.2(b). 
 (a) The first installment of the Purchase Price shall be paid at the Closing. The
aggregate amount of the first installment of the Purchase Price shall be $1,600,000 in U.S. currency. 
 (b) The second
installment of the Purchase Price shall be paid at the earlier of (i) the initiation by the Acquirer of IND-enabling studies for a Neuro3D Compound; and (ii) the first anniversary of the Closing Date. The aggregate amount of the second
installment of the Purchase Price shall be $200,000 in U.S. currency.” 

 (b) Indemnification. Section 8 of the Purchase Agreement is hereby deleted in
its entirety, and the following new Section 8 shall be substituted in lieu thereof: 
 “8. INDEMNIFICATION. 
 8.1. By the Company. From and after the Closing Date, to the extent provided in this Section 8, the Company shall indemnify
and hold harmless the Acquirer, and its successors and assigns, and its officers and directors (each, an “Indemnified Party”) from and against any Liabilities, claims, demands, judgments, losses, costs, damages or expenses whatsoever
(including reasonable attorneys’ fees incurred by such Indemnified Party in connection therewith) (collectively, “Damages”) that such Indemnified Party may sustain, suffer or incur and that result from, arise out of or relate to
(a) any breach of any representation, warranty, covenant or agreement of the Company contained in this Agreement, whether or not involving a third-party claim, (b) any Litigation affecting the Company or the Acquired Assets that arose from
any matter or state of facts existing prior to the Closing, (c) any Retained Liabilities, or (d) the failure by the Company to comply with the provisions of the laws of any jurisdiction relating to the transfer of assets which may be
applicable to the transfer of the Acquired Assets; provided that the foregoing indemnification shall not apply to any Damage to the extent such Damage is caused by the breach of this Agreement or the negligence or willful misconduct of the Acquirer
or its Affiliates and their current or former employees, officers and directors or is otherwise subject to an obligation by Acquirer to indemnify Company under section 8.2. 
 8.2 By the Acquirer. From and after the Closing Date, to the extent provided in this Section 8, the Acquirer shall indemnify
and hold harmless the Company, the Stockholders, their heirs, legal representatives, successors and assigns (each, an “Indemnified Party”) from and against any Damages that such Indemnified Party may sustain, suffer or incur and that
result from, arise out of or relate to (a) any breach of any representation, warranty, covenant or agreement of the Acquirer contained in this Agreement, whether or not involving a third-party claim, (b) the failure by the Acquirer to
comply with the provisions of the laws of any jurisdiction relating to the transfer of assets which may be applicable to the transfer of the Acquired Assets, or (c) any liability arising out of the development or exploitation of the Acquired
Assets by the Acquirer or its Affiliates including without limitation clinical trials and product sales, other than any liability arising out of or relating to any matter or state of facts existing prior to the Closing Date; provided that the
foregoing indemnification shall not apply to any Damage to the extent such Damage is caused by the breach of this Agreement or the negligence or willful misconduct of the Company or its Affiliates and their current or former employees, officers and
directors or is otherwise subject to an obligation by the Company to indemnify the Acquirer under section 8.1. 
 8.3
Procedure for Claims. 
 (a) An Indemnified Party that desires to seek indemnification under any part of this
Section 8 shall give notice (a “Claim Notice”) to each Party responsible or alleged to be responsible for indemnification hereunder (an “Indemnitor”) prior to any applicable Expiration Date specified below. Such notice shall
briefly explain the nature of the claim and shall specify the amount thereof. If the matter to which a claim relates shall not have been resolved as of the date of the Claim Notice, the Indemnified Party shall estimate the amount of the claim in the
Claim Notice, but also specify therein that the claim has not 

  

 2 

 
yet been liquidated (an “Unliquidated Claim”). If an Indemnified Party gives a Claim Notice for an Unliquidated Claim, the Indemnified Party shall
also give a second Claim Notice (the “Liquidated Claim Notice”) within 60 days after the matter giving rise to the claim becomes finally resolved, and the Second Claim Notice shall specify the amount of the claim. Each Indemnitor to which
a Claim Notice is given shall respond to any Indemnified Party that has given a Claim Notice (a “Claim Response”) within 20 days (the “Response Period”) after the later of (i) the date that the Claim Notice is given or
(ii) if a Claim Notice is first given with respect to an Unliquidated Claim, the date on which the Liquidated Claim Notice is given. Any Claim Notice or Claim Response shall be given in accordance with the notice requirements hereunder, and any
Claim Response shall specify whether or not the Indemnitor giving the Claim Response disputes the claim described in the Claim Notice. If any Indemnitor fails to give a Claim Response within the Response Period, such Indemnitor shall be deemed not
to dispute the claim described in the related Claim Notice. If any Indemnitor elects not to dispute a claim described in a Claim Notice, whether by failing to give a timely Claim Response or otherwise, then the amount of such claim shall be
conclusively deemed to be an obligation of such Indemnitor. 
 (b) If any Indemnitor shall be obligated to indemnify an
Indemnified Party hereunder, such Indemnitor shall pay to such Indemnified Party within 30 days after the last day of the Response Period the amount to which such Indemnified Party shall be entitled. If the Acquirer shall be the Indemnified Party,
it shall seek indemnification directly from the Company for the payment of any Damages. If the Company or a stockholder shall be the Indemnified Party, he, she or it shall seek indemnification directly from the Acquirer. If any Indemnified Party
fails to receive all or part of any indemnification obligation when due, then such Indemnified Party shall also be entitled to receive from the applicable Indemnitor interest on the unpaid amount for each day during which the obligation remains
unpaid at an annual rate equal to the applicable short term federal rate for federal income tax purposes in effect on the date of expiration of said 30-day period (“Prime Rate”), and the Prime Rate in effect on the first business day of
each calendar quarter shall apply to the amount of the unpaid obligation during such calendar quarter. 
 8.4 Claims
Period. Any claim for indemnification under this Section 8 shall be made by giving a Claim Notice under Section 8.3 on or before the applicable “Expiration Date” specified below in this Section 8.4, or the claim under
this Section 8 shall be invalid. The following claims shall have the following respective “Expiration Dates”: (a) for a period of twenty (20) years after the Closing Date for any claim for Damages related to any action,
suit, litigation, or other proceeding arising out of the Company’s use of any compounds or other Acquired Assets in a clinical trial (a “Clinical Trial Proceeding”); and (b) the second anniversary of the Closing Date for any
other claims. If more than one of such Expiration Dates applies to a particular claim, the latest of such Expiration Dates shall be the controlling Expiration Date for such claim. So long as an Indemnified Party in good faith gives a Claim Notice
for an Unliquidated Claim on or before the applicable Expiration Date, such Indemnified Party shall be entitled to pursue its rights to indemnification regardless of the date on which such Indemnified Party gives the related Liquidated Claim Notice.

  

 3 

 8.5 Third Party Claims. An Indemnified Party that desires to seek indemnification
under any part of this Section 8 with respect to any actions, suits or other administrative or judicial proceedings (each, an “Action”) that may be instituted by a third party shall give each Indemnitor prompt notice of a third
party’s institution of such Action. After such notice, any Indemnitor may, or if so requested by such Indemnified Party, any Indemnitor shall, participate in such Action or assume the defense thereof, with counsel satisfactory to such
Indemnified Party; provided, however, that such Indemnified Party shall have the right to participate at its own expense in the defense of such Action; and provided, further, that the Indemnitor shall not consent to the entry of any judgment or
enter into any settlement, except with the written consent of such Indemnified Party (which consent shall not be unreasonably withheld), that (a) fails to include as an unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all Liability in respect of any such Action or (b) grants the claimant or plaintiff any injunctive relief against the Indemnified Party. Any failure to give prompt notice under this Section 8.5 shall not
bar an Indemnified Party’s right to claim indemnification under this Section 8, except to the extent that an Indemnitor shall have been harmed by such failure. 
 8.6 Limitation of Liability. Neither Party shall be liable to the other for consequential, indirect or punitive damages. For the
avoidance of doubt, no Party can recover from the other Party more than once for a single cause of action under indemnity granted by the Indemnitor pursuant to this Agreement. The foregoing sentence shall not be construed to preclude recovery in
respect of multiple claims arising from a single event or series of events. Neither party shall have liability with respect to any breach of any such Party’s representations and warranties under this Agreement for any individual item where the
Damages relating thereto is less than ten thousand Euros (€10,000), but when Damages exceed such amount then the Indemnitor shall be liable for the entire amount of the Damages. Each Party shall take and shall cause its Affiliates to take all
reasonable steps to mitigate any Damages. The cumulative amount of Damages awarded to the Acquirer, including without limitation the Damages awarded in accordance with the last sentence of this Section 8.6 shall not exceed $2,600,000; except
for Damages that the Acquirer (or any Acquirer Indemnified Party) may incur and that result from, arise out of or relate to any Litigation affecting the Company or the Acquired Assets that arises from any matter or state of facts existing prior to
the Closing (including, without limitation, any Clinical Trial Proceeding). Notwithstanding anything to the contrary contained in this Agreement, the cumulative amount of Damages awarded to the Acquirer that result from, arise out of, or relate to
any breach, violation or inaccuracy of any representation or warranty made by the Company in Section 4.7 hereof (Intellectual Property) or any other provision of this Agreement to the extent the claim for which indemnification under this
Agreement is sought is covered by the subject matter of Section 4.7 hereof, shall not exceed $2,600,000.” 
 3.
Ratification. Except as expressly amended hereby, all of the terms, provisions and conditions of the Purchase Agreement are hereby ratified and confirmed in all respects by each party hereto and, except as expressly amended hereby, are, and
hereafter shall continue, in full force and effect, including without limitation, all time periods provided in the Purchase Agreement. 
  

 4 

 4. Contents of Agreement. This Amendment, together with the Purchase Agreement and other
Transaction Documents, sets forth the entire understanding of the Parties hereto with respect to the Transactions and supersedes all prior agreements or understandings among the Parties regarding those matters. 
 5. Amendments, Severability, etc. This Amendment may be amended, modified or supplemented only by a written instrument duly executed by each of
the Parties hereto. If any provision of this Amendment shall for any reason be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision hereof, and this
Amendment shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. This Amendment shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, legal representatives,
successors and permitted assigns of the Parties hereto. 
 6. Counterpart Signatures. This Amendment may be executed in one or more
counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. 
 7.
Governing Law; Submission to Jurisdiction. 
 (a) ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY AND
INTERPRETATION OF THIS AMENDMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER
JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK. NOTWITHSTANDING THE FOREGOING, ALL QUESTIONS CONCERNING THE PERSONAL LIABILITY OF THE SHAREHOLDERS OF THE COMPANY SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF FRANCE. 
 (b) Any legal action or other legal proceeding relating to this
Amendment or the enforcement of any provision of this Amendment may be brought or otherwise commenced in any state or federal court located in the State of New York or the State of California. Each party to this Amendment: 
 (i) expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of New York or
the State of California (and each appellate court located in such State) in connection with any such legal proceeding; 
 (ii)
agrees that each state and federal court located in the State of New York or the State of California shall be deemed to be a convenient forum; and 
 (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding commenced in any state or federal court located in the State of New York or the State of California, any claim
that such party is not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient forum, 

  

 5 

 
that the venue of such proceeding is improper or that this Amendment or the subject matter of this Amendment may not be enforced in or by such court.

 8. Recordation of this Amendment. It is understood and acknowledged by both parties to this Amendment that certain countries may
require that this Amendment be recorded. The Company shall, at the Company’s expense, promptly cause this Amendment to be recorded in France. The Acquirer shall be responsible for the recordation costs in any other jurisdiction in which the
Acquirer determines to record this Amendment. 
 [signatures on following page] 
  

 6 

 IN WITNESS WHEREOF, this Amendment has been executed by the Parties hereto as of the day and year first
written above. 
  

			
	VIA PHARMACEUTICALS, INC.
		
	By:	 	/s/ Lawrence K. Cohen
	Name:	 	Lawrence K. Cohen
	Title:	 	Chief Executive Officer

  

			
	NEURO3D, S.A.
		
	By:	 	/s/ Charles Woler
	Name:	 	Charles Woler
	Title:	 	Chief Executive OfficerExclusive Option Agreement

 Exhibit 10.8 
 EXCLUSIVE OPTION AGREEMENT 
 THIS AGREEMENT is made and entered into as of 27 day of March
(the “Effective Date”) by and between SANTEN PHARMACEUTICAL CO., LTD. (“SANTEN”), a Japanese corporation having a place of business at 9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka 533-8651, Japan, and VIA
PHARMACEUTICALS, INC. (“VIA”), a Delaware corporation having a place of business at 750 Battery Street, Suite 330, San Francisco, CA 94111, USA. 
 WHEREAS, SANTEN has developed and owns certain compounds generally characterized as leukotriene A4 hydrolase inhibitors and their related compounds (the “Compounds”), and owns the patents and proprietary
information relating thereto; 
 WHEREAS, SANTEN has provided certain confidential information relating to the Compounds to VIA under the
confidentiality agreement between the parties dated February 20, 2006 (the “Confidentiality Agreement”); 
 WHEREAS, VIA
desires to perform certain studies with some of the Compounds to determine its interest in getting a license from SANTEN for the Compounds; 
 WHEREAS, SANTEN is willing to grant VIA an exclusive option for the license under the terms and conditions set forth herein; 
 NOW,
THEREFORE, the parties hereto agree as follows: 
 1. DEFINITIONS 
  

	1.1	“Know-How” shall mean (a) Confidential Information (as defined in the Confidentiality Agreement) disclosed by SANTEN to VIA under the Confidentiality Agreement and
this Agreement and (b) any technical information, trade secret, know-how or data developed or owned by SANTEN prior to the effective date of the License Agreement (as hereinafter defined) relating to the Materials (as hereinafter defined) which
are not covered by the Patent Rights (as hereinafter defined). 

  

	1.2	“License Agreement” shall mean the exclusive license agreement to be entered into between SANTEN and VIA relating to the Product (as hereinafter defined) if VIA exercises
the option pursuant to Section 4.1. 

  

	1.3	“Materials” shall mean the Compounds specifically listed in Exhibit C attached hereto. 

  

	1.4	“Option Period” shall mean the period commencing on the Effective Date and, unless earlier terminated by VIA pursuant to Section 2.3, ending upon the expiration of a
period of twelve (12) months following the date of receipt by VIA of the Materials provided by SANTEN pursuant to Section 5.2. 

  

	1.5	“Patent Rights” shall mean the issued patents listed in Exhibit A attached hereto. 

	1.6	“Product” shall mean any form or dosage of pharmaceutical preparations, including combinations and conjugates, which contains as an active ingredient any one of the
Materials and other compounds, including, without limitation, any salt, form and derivative thereof, that are claimed in the Patent Rights. 

  

	1.7	“Study” shall mean the experimental investigation conducted by VIA using the Materials during the Option Period to determine whether to exercise the option granted
hereunder. 

 2. OPTION FOR EXCLUSIVE LICENSE 
  

	2.1	SANTEN hereby grants to VIA an exclusive option to acquire an exclusive worldwide license (including the right to sublicense) under the Patent Rights and the Know-How to make, have
made, use, sell, have sold, offer to sell and import the Product(s) for all indications excluding the ophthalmic diseases in all territories of the world. 

  

	2.2	If VIA elects to exercise its exclusive option to acquire an exclusive license under Section 2.1, VIA shall notify SANTEN in writing of its intent to exercise its option prior
to the expiration of the Option Period. Failure of VIA to provide notice prior to the expiration of the Option Period shall be deemed a waiver by VIA of its option. 

  

	2.3	VIA may notify SANTEN at any time during the Option Period if VIA has determined not to exercise the option granted under Section 2.1. The option granted hereunder shall
terminate upon receipt by SANTEN of such notice. 

  

	2.4	During the Option Period, VIA shall have the right to conduct the Study with the Materials in accordance with the provisions of Section 5. 

  

	2.5	During the term of this Agreement, SANTEN shall not grant, or offer to grant, to any party any license under the Patent Rights and the Know-How to make, use and sell the Products.

 3. CONSIDERATION 
  

	3.1	In consideration of the exclusive option granted to VIA herein, VIA shall pay to SANTEN a non-refundable, non-creditable option fee of twenty-five thousand U.S. dollar (US$25,000)
within thirty (30) days following the Effective Date. 

  

	3.2	The option fee shall be paid by bank wire transfer in immediately available funds in United States dollar to such bank account as is designated in writing by SANTEN.

 4. NEGOTIATION AND TERMS OF LICENSE AGREEMENT 
  

	4.1	Upon notice of the option exercise by VIA pursuant to Section 2.2, SANTEN and VIA shall enter into good faith negotiations regarding the terms and conditions of the License
Agreement and shall agree to execute the License Agreement within three (3) months from the date of receipt by SANTEN of such notice. 

  

 2 

	4.2	The terms and conditions of the License Agreement shall contain the terms outlined in Exhibit B and other reasonable commercial terms customary for agreements of this type.

 5. SUPPLY AND EVALUATION OF MATERIALS 
  

	5.1	SANTEN shall supply VIA with the Materials listed in Section 1 of Exhibit C in the respective amounts specified therein free of charge within one (1) month following the
Effective Date. 

  

	5.2	SANTEN shall commence synthesis of the Materials listed in Section 2 of Exhibit C upon the Effective Date and shall supply such Materials to VIA upon completion of the
synthesis. All reasonable and verifiable out-of-pocket expenses incurred by SANTEN for the synthesis of such Materials shall be borne by VIA. The payment by VIA for such expenses shall be made within one (1) month after receipt by VIA from
SANTEN of an invoice specifying such expenses. 

  

	5.3	Any Materials exceeding the amounts specified in Exhibit C will be supplied only if it is available from SANTEN during the Option Period. Any Materials that are not available from
SANTEN will be synthesized by SANTEN provided that all reasonable and verifiable out-of-pocket expenses incurred by SANTEN and agreed to by VIA for the synthesis of such Materials shall be paid by VIA. 

  

	5.4	VIA shall use commercially reasonable efforts to perform the Study during the Option Period. VIA shall not make use of the Materials for any unlawful or unauthorized purposes,
including the use in human, other than permitted in this Agreement. VIA further agrees not to synthesize or modify any Materials or its peripheral compounds. 

  

	5.5	VIA may transfer or disclose the Materials to any contract research organization (“CRO”) solely in order to conduct the Study by giving SANTEN a written notice specifying
such CRO. VIA may have all or part of the Study performed by a third party, provided that any such CRO agrees in writing to be bound by the confidentiality and non-use obligations consistent with those contained in this Agreement and provided
further that VIA shall be jointly and severally liable for any unauthorized disclosure or use of the Materials by such third party. 

  

	5.6	If reasonably requested by SANTEN during the Option Period, VIA shall provide SANTEN with an update on the progress of the Study including, but not limited to, the experimental
protocols, schedule, evaluation status and interim results of the Study. At the completion of the Study but no later than the expiration of the Option Period, VIA shall furnish SANTEN with all data and information generated in connection with the
Study. VIA agrees not to use for any purpose, disclose to any third party, or publish such data and information without prior written consent of SANTEN. 

  

	5.7	 THE MATERIALS ARE FOR NON-CLINICAL RESEARCH PURPOSES ONLY AND ARE PROVIDED WITHOUT WARRANTY AS TO ITS PROPERTIES, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE AND WITHOUT ANY OTHER WARRANTY WHATSOEVER, EXPRESS OR IMPLIED. VIA AGREES THAT IN NO EVENT SHALL SANTEN BE LIABLE FOR ANY USE 

  

 3 

	 	 
OF THE MATERIALS BY VIA AND IT SHALL INDEMNIFY AND HOLD SANTEN HARMLESS FROM ANY AND ALL CLAIMS, SUITS AND LIABILITIES ARISING FROM ITS USE OF THE MATERIALS.

  

	5.8	VIA acknowledges that the Materials are the sole property of SANTEN and that, upon expiration of the Option Period, it will return all unused Materials. Nothing in this Agreement
shall be construed as granting VIA any license or right to the Materials unless VIA and SANTEN have entered into the License Agreement pursuant to Section 4. 

  

	5.9	VIA shall promptly disclose to SANTEN any and all discoveries or inventions made by or for VIA in connection to the Materials or Study. VIA shall assign all intellectual property
rights in such discoveries or inventions to SANTEN and shall procure such an assignment from the inventor(s) where applicable. VIA further agrees to execute all relevant documents and assignments and do all such further things as may be necessary to
perfect SANTEN’s title to such discoveries or inventions. The intellectual property rights covering such discoveries or inventions shall be added to the Patent Rights or the Know-How under which the exclusive license will be granted to VIA.

  

	5.10	SANTEN agrees to prosecute and maintain all of the patents and applications included within the Patent Rights in all countries where such Patent Rights are now issued or pending, at
its sole cost and expense. 

 6. CONFIDENTIALITY 
  

	6.1	The provisions of the Confidentiality Agreement shall be applied to any Confidential Information disclosed by either party to the other in connection with this Agreement.

  

	6.2	Notwithstanding the provision of Section 6.1, the data and information furnished by VIA to SANTEN under Section 5.6 shall be regarded as Confidential Information owned and
disclosed by SANTEN and shall be subject to the confidentiality and non-use obligations applicable to VIA under the Confidentiality Agreement. 

 7. TERM AND TERMINATION 
  

	7.1	This Agreement shall become effective upon the Effective Date and, unless earlier terminated pursuant to Section 7.2, 7.3 or 7.4, shall remain in effect until the expiration of
the Option Period. 

  

	7.2	VIA may terminate this Agreement at any time by providing written notice to SANTEN. 

  

	7.3	If either party fails to perform or violates any material obligation of this Agreement, and the default or breach is not cured within thirty (30) days of receiving of notice
specifying the default or breach, then non-delinquent party may terminate this Agreement forthwith. 

  

	7.4	If one of the parties shall go into liquidation, or a receiver or trustee be appointed for its property or estate, or if such party shall make an assignment for the benefit of its
creditors, and whether or not any of the aforesaid acts be the outcome of a voluntary act of that party, the other party shall be entitled to terminate this Agreement forthwith by written notice to the first party. 

  

 4 

	7.5	Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of
Sections 5.7, 5.9, 6, 8.3 and 8.4 shall survive the expiration or termination of this Agreement. 

 8. MISCELLANEOUS

  

	8.1	Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and shall be deemed to have been given at the time when actually received as a
consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, delivery by a professional courier service or certified or registered mail addressed to the party at the address below or at
such changed address as the party shall have specified by written notice: 

  

			
	To Santen:	  	 Santen Pharmaceutical Co., Ltd.
 9-19, Shimoshinjo
3-chome, Higashiyodogawa-ku,
 Osaka 533-8651, Japan
 Facsimile:
+81-6-6321-3723
 Attn: Mitsushi Hikida, Ph.D.

		
	To VIA:	  	 VIA Pharmaceuticals, Inc.
 750 Battery Street, Suite
330
 San Francisco, CA 94111, USA
 Facsimile: +1-415-283-2201

 Attn: Lawrence Cohen, Ph.D.

  

	8.2	Neither this Agreement nor any rights or obligations hereunder shall be assignable by either party hereto without prior written consent of the other party, and any attempted without
the express prior written consent shall be null and void. However, either party shall have the right to assign this Agreement without obtaining the consent of the other party but with written notification to such other party in connection with a
transfer of substantially all of its business or assets to which this Agreement relates. 

  

	8.3	This Agreement shall be construed and interpreted in accordance with the Japanese law without giving effect to its principles of conflict of laws. 

  

	8.4	All disputes, controversies or differences which may arise between the parties hereto, out of or in relation to or in connection with this Agreement shall be finally settled by
arbitration to be held in Osaka, Japan in accordance with the Commercial Arbitration Rules of The Japan Commercial Arbitration Association. The award rendered by the arbitrator(s) shall be final and binding upon the parties hereto.

  

	8.5	The provisions of this Agreement shall be deemed to be severable, and any invalidity of any provision of this Agreement shall not affect the validity of the remaining provisions of
this Agreement. 

  

 5 

	8.6	This Agreement and the Confidentiality Agreement constitute the entire agreement and understanding between the parties with respect to the subject matter and supersedes any prior
agreement or understandings relating to the subject matter of this Agreement. This Agreement can be modified or amended only by a written instrument signed by duly authorized representatives of the parties. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in duplicate on the date first above written. 
  

					
	VIA PHARMACEUTICALS, INC.	 		 	SANTEN PHARMACEUTICAL CO., LTD.
			
	/s/ Lawrence Cohen	 		 	/s/ Toshiaki Nishihata
	 Lawrence Cohen, Ph.D.
 Chief Executive
Officer
	 		 	 Toshiaki Nishihata, Ph.D.
 Head of R& D Division

	Date: 2/21/07	 		 	Date: 3/27/07

  

 6 

 Exhibit A 
 Patent Rights 
  

											
	 Country
	  	Appln. No.	  	Appln. Date	  	Patent No.	  	Regist. Date	  	Expir. Date
	
	 Novel amino acid derivative(s) having N,N-dialkylaminophenyl group

						
	 USA
	  	08/913,093	  	09/05/1997	  	5,872,281	  	02/16/1999	  	03/05/2016
	 Europea)
	  	96904324.9	  	03/05/1996	  	0870762	  	04/28/2004	  	03/05/2016
	
	 a):    UK, Germany, France, Italy, Switzerland/Liechtenstein

	
	 Novel sulfur-containing amino-acid derivatives

						
	 USA
	  	09/254,160	  	03/01/1999	  	6,046,235	  	04/04/2000	  	09/05/2017
	 Europeb)
	  	97939187.7	  	09/05/1997	  	0947502	  	06/21/2006	  	09/05/2017
	 Japan
	  	H09-240109	  	09/05/1997	  	3608021	  	10/22/2004	  	09/05/2017
	
	 b):    UK, Germany, France, Italy, Spain

	
	 Leukotriene A4 hydrolase inhibitors

						
	 USA
	  	09/381,256	  	09/17/1999	  	6,242,476	  	06/05/2001	  	03/25/2018
	 Europec)
	  	98910975.6	  	03/25/1998	  	0979817	  	07/27/2006	  	03/25/2018
	 Japan
	  	H09-74780	  	03/27/1997	  	3196106	  	06/08/2001	  	03/27/2017
	
	 c):    UK, Germany, France, Italy, Spain

  

 7 

 Exhibit B 
 Terms for License Agreement 
  

			
	License Grant:	  	 VIA shall have an exclusive license under the Patent Rights and the Know-How, including the unrestricted right to sublicense, to make, have made,
use and sell, have sold, offer to sell and import the Product for all indications excluding the ophthalmic diseases* in all territories of the world. Notwithstanding the foregoing, SANTEN shall reserve the right to co-distribute the Product for
treatment of rheumatoid arthritis in Japan.
  
 *Note: The right for the ophthalmic
disease shall be discussed and determined at the time of concluding the License Agreement.

		
	Milestone Payments:	  	In consideration of the license granted to VIA, VIA shall pay SANTEN the following milestones during the Term (as hereinafter defined) on the first Product developed by VIA or its
sublicensees (for clarification, each milestone is to be paid a maximum of one time):

  

				
	 Milestone
	  	Payment
	 Execution of the License Agreement
	  	$	350,000
	 Enrollment of the first subject to the first Phase I clinical trial
	  	$	750,000
	 Enrollment of the first subject to the first Phase II clinical trial
	  	$	1,000,000
	 Enrollment of the first subject to the first Phase III clinical trial
	  	$	2,000,000
	 First NDA approval in the U.S.
	  	$	4,000,000
	 First MA in one of the following countries: U.K., France, Italy, Germany, Spain
	  	$	2,000,000

  

			
	Royalties:	  	VIA shall pay to SANTEN the following royalties on annual worldwide net sales of Product during the Term.

  

				
	 On the first $250 million
	  	3.5	%
	 On the next $250 million
	  	4.0	%
	 Thereafter
	  	4.5	%

  

			
	Term:	  	“Term” means the period commencing on the effective date of the License Agreement and ending upon the later of (a) the expiration of the last to expire of the Patent Rights or
(b) ten (10) years from the date of the first commercial sale of Product on a country-by-country basis.

  

 8 

			
		
		  	Upon the expiration of the Term in each country, the license granted shall be deemed to be perpetual, irrevocable and fully-paid up with respect to Product in such country.
		
	Termination:	  	VIA may terminate the License Agreement by sixty (60) days written notice to SANTEN. Upon termination, VIA shall transfer NDA or MA to SANTEN free of charge.
		
	Manufacturing:	  	If requested by VIA, SANTEN will transfer to VIA or the party designated by VIA the Know-How reasonably required for manufacture of the Materials developed by VIA. The terms and conditions
for the transfer shall be separately discussed and agreed.
		
	Miscellaneous:	  	The License Agreement will contain other terms and conditions customary for agreements of this type.

  

 9 

 Exhibit C 
  

	 	1.	Materials to be provided by SANTEN within thirty (30) days following the Effective Date: 

  

					
	1.	  	SA 6541	  	100 mg
	2.	  	SA 8395	  	20 mg
	3.	  	SA 8621	  	20 mg
	4.	  	SA 9499	  	100 mg

  

	 	2.	Materials to be synthesized and provided by SANTEN: 

  

					
	1.	  	SA 9226	  	100 mg
	2.	  	SA 9524	  	100 mg
	3.	  	SA 8862	  	100 mg

  

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]